Biomarkers For Thyroid Dysfunction In Diabetes: New Insights And Future Directions

Thyroid dysfunction and diabetes mellitus are two closely related metabolic health conditions. The bidirectional relationship between these disorders emphasizes the need to elucidate their common pathophysiology and to identify biomarkers for early diagnosis and treatment. This review summarizes recent advances in biomarker identification for thyroid dysfunction in diabetic populations, describes its clinical application, and maps out future directions in research and therapeutics. A review of literature from 2014 to 2024 was performed, including studies that investigated the conventional and emerging biomarkers for thyroid dysfunction in diabetes. The analysis also includes the incorporation of artificial intelligence (AI) in biomarker discovery and advancement in analytical techniques. Although conventional biomarkers such as TSH, free T3, and free T4 are still important in determining thyroid dysfunction, they are confounded by glycemic control, comorbidities, and polypharmacy. Additional diagnostic precision is provided by emerging biomarkers, including reverse T3, cytokines, and genetic markers. With highly sensitive assays and omics technology together with artificial intelligence and big data analytics, novel biomarker discovery can be achieved, and personalized medicine approaches made feasible. The integration of advanced biomarker research with novel technologies may provide a means to improve the diagnostic accuracy and therapeutic strategy for thyroid dysfunction in diabetes. Future studies should focus on validating new biomarkers, understanding molecular pathways using AI for predictive modeling, and developing individualized treatment.